ArticleJBMR plus2026
Bone fragility in a post-intestinal transplant patient with mesenteric heterotopic ossification.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterotopic ossification (HO) is the aberrant formation of mature lamellar bone in extraskeletal tissues, most commonly following trauma or surgery. Mesenteric involvement is rare and often discovered incidentally. We report the case of a 44-yr-old man with mesenteric HO in the setting of multiple emergent abdominal surgeries after a motor vehicle accident. Histopathology confirmed bone with cartilage and BM within the mesentery. He subsequently required an isolated small-intestinal transplantation for short gut syndrome. Following transplantation, the patient developed multiple vertebral compression fractures in the setting of bone fragility due to chronic antirejection medications and high-dose steroid use. He received more than a decade of treatment with zoledronic acid, with stabilization of BMD and no additional fractures. He was later transitioned to denosumab. This case underscores the rarity of HO occurring in the mesentery and highlights the challenges of managing bone fragility in high-risk post-intestinal transplant patients. This case highlights the importance of monitoring and managing bone fragility in patients undergoing intestinal transplantation and long-term immunosuppressive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.